Restrictions Reintroduced

The FDA uses the safety review to tighten mifepristone access, most likely by revisiting changes made since 2016 and 2021. The agency could argue that data gaps around telehealth and mail dispensing justify a more restrictive REMS, even if litigation quickly follows.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.